21 December 2023
21 December 2023
Tusamitamab ravtansine did not meet the primary endpoint of progression-free survival versus docetaxel in the CARMEN-LC03 trial.
Dose one of PBFT02 was found to be well-tolerated in subjects who received an improved steroid regimen for immunosuppression.
Gore initiated the early feasibility ARISE trial in 2018, publishing results in the Journal of Endovascular Therapy last year.
More than 800 participants across the world have received the LNK01001 treatment so far as part of trials.
Decentralisation, diversity, new trial systems and transparency rules made a mark in 2023, but increasing pressure on sponsors may backfire.
The company anticipates reporting topline data from the STAR-1 trial in the first quarter of 2025.
The life sciences sector is set to see a significant amount of change in 2024.
The company has successfully enrolled all participants with Crohn’s disease and ulcerative colitis in the neuromodulation study.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
